Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.34 |
| ▸ | CA1 | P00915 | 9/20 | 0.34 |
| ▸ | CA2 | P00918 | 9/20 | 0.34 |
| ▸ | CA9 | Q16790 | 9/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15927272 | 0.89 | CYP2D6 (0.38) | CA12CA1CA2CA9MAPT | |
| SCHEMBL13938174 | 0.78 | THRB (0.47) | CA12CA1CA2CA9MAPT | |
| SCHEMBL19396312 | 0.78 | THRB (0.47) | CA12CA1CA2CA9MAPT | |
| SCHEMBL17521873 | 0.78 | THRB (0.47) | CA12CA1CA2CA9MAPT | |
| SCHEMBL15927275 | 0.76 | SLC2A1 (0.37) | CA2 | |
| SCHEMBL14172498 | 0.74 | CA12 (0.45) | CA12CA1CA2CA9MAPT | |
| SCHEMBL21454715 | 0.73 | THRB (0.48) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL17521934 | 0.72 | CA2 (0.43) | CA12CA1CA2CA9MAPT | |
| SCHEMBL15927236 | 0.70 | CA12 (0.42) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL18272669 | 0.70 | THRB (0.47) | CA12CA1CA2CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC. (CA) | 2017-04-06 | — | — | US | disclosed |
| US-9499480-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2016-11-22 | — | — | US | disclosed |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LIMITED PARTNERSHIP (CA) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA12 1242/4885CA1 119/4885CA2 1659/4885 |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA12 1224/4885CA1 109/4885CA2 1611/4885 |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | CA12 1242/4885CA1 119/4885CA2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.